Search tips
Search criteria 


Logo of canmedajCMAJ Information for AuthorsCMAJ Home Page
Can Med Assoc J. 1983 January 1; 128(1): 24–26.
PMCID: PMC1874707

The status of metformin in Canada.


During the 1970s two biguanide drugs, phenformin and metformin, were used to control hyperglycemia. Phenformin was phased out of the Canadian market because it carried an unacceptable risk of causing lactic acidosis, but metformin remains available. All documented cases of lactic acidosis associated with metformin administration, which are rare, have occurred abroad in patients who were taking the drug in spite of having contraindications to its use. The two drugs are metabolized differently, phenformin being deactivated and concentrated in the liver, and metformin being excreted rapidly, unchanged, by the kidneys. In properly selected diabetic patients therapeutic doses of metformin do not raise the blood levels of intermediary metabolites enough to induce ketoacidosis or lactic acidosis. The safety of the drug is supported by the clinical experience over about 56,000 patient-years in Canada.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (684K), or click on a page image below to browse page by page.

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association